Phase 3 trial in 663 patients with locally advanced rectal cancer and uninvolved mesorectal fascia: non-inferiority of neoadjuvant CAPOX vs capecitabine chemoradiation was not confirmed (3-year LRRFS 96.3% vs 97.4%; HR 1.40); long-term grade 2-4 AEs were lower (16.0% vs 26.3%).
RCTn = 663
Mei et al. Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial